首页 > 最新文献

Journal of Research in Medical Sciences最新文献

英文 中文
Comparison of complete blood count parameters in different severity of proteinuria among patients with type 2 diabetes mellitus. 2型糖尿病不同程度蛋白尿患者全血细胞计数参数的比较。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_150_24
Amirhesam Alirezaei, Kimia Karimi Toudeshki, Masoumeh Taherian, Hadi Pashapour, Fatemeh Rahmani, Najmeh Norouzi, Seyed Amirhossein Fazeli

Background: Proteinuria is a key indicator of kidney damage in diabetic nephropathy, and its severity correlates with the progression of the disease. In diabetic patients, it is crucial to identify reliable predictors for proteinuria and its severity for early detection and management of kidney damage.

Materials and methods: This cross-sectional study was conducted from November 16, 2022, to May 20, 2023, on patients with type 2 diabetes mellitus (T2DM) who were outpatients at clinics of Shahid Modarres Hospital, Tehran, Iran. Participants were categorized based on their level of proteinuria during 24-h as follows: group A1 (normal to mildly increased proteinuria), Group A2 (moderately increased proteinuria), and Group A3 (severely increased proteinuria). Then, complete blood cell count and other laboratory parameters, were compared between study groups.

Results: In this cross-sectional study, 128 participants, including 53 (41.4%) men and 75 (58.6%) women with T2DM, were enrolled. The mean age of participants was 56.40 ± 13.31 years. Although there were no significant differences between cell count and parameters of three groups, a statistically significant difference was seen in neutrophil-to-lymphocyte ratio (NLR) (1.93 ± 0.76, 2.34 ± 0.93, and 2.73 ± 1.07 in A1, A2, and A3 groups, respectively; P = 0.003). Further analysis showed that NLR was significantly higher in Group A3 compared to A1 (2.73 ± 1.07 vs. 1.93 ± 0.76, respectively; P = 0.006), but there was no significant difference between Groups A3 and A2 (2.73 ± 1.07 vs. 2.34 ± 0.93, respectively; P = 0.482) and between Groups A2 and A1 (2.34 ± 0.93 vs. 1.93 ± 0.76, respectively; P = 0.257).

Conclusion: Overall, this study suggests that some routine laboratory parameters may be associated with proteinuria and its severity in patients with T2DM. NLR, in particular, showed this association in our study, promising future studies evaluating this association and whether it can help as a predictor or not.

背景:蛋白尿是糖尿病肾病肾损害的一个关键指标,其严重程度与疾病的进展相关。在糖尿病患者中,确定蛋白尿及其严重程度的可靠预测指标对于早期发现和管理肾损害至关重要:这项横断面研究于 2022 年 11 月 16 日至 2023 年 5 月 20 日在伊朗德黑兰 Shahid Modarres 医院门诊部对 2 型糖尿病(T2DM)患者进行了调查。根据 24 小时蛋白尿水平将参与者分为以下三组:A1 组(蛋白尿正常至轻度增加)、A2 组(蛋白尿中度增加)和 A3 组(蛋白尿严重增加)。然后比较研究组之间的全血细胞计数和其他实验室参数:在这项横断面研究中,共有 128 名 T2DM 患者参加,包括 53 名男性(41.4%)和 75 名女性(58.6%)。参与者的平均年龄为 56.40±13.31 岁。虽然三组的细胞计数和参数无明显差异,但中性粒细胞与淋巴细胞比值(NLR)有显著统计学差异(A1、A2 和 A3 组分别为 1.93 ± 0.76、2.34 ± 0.93 和 2.73 ± 1.07;P = 0.003)。进一步分析显示,A3 组的 NLR 明显高于 A1 组(分别为 2.73 ± 1.07 vs. 1.93 ± 0.76;P = 0.006),但 A3 组与 A2 组之间(分别为 2.73 ± 1.07 vs. 2.34 ± 0.93;P = 0.482)以及 A2 组与 A1 组之间(分别为 2.34 ± 0.93 vs. 1.93 ± 0.76;P = 0.257)无明显差异:总之,本研究表明,一些常规实验室参数可能与 T2DM 患者的蛋白尿及其严重程度有关。尤其是 NLR,在我们的研究中显示出了这种关联性,有望在未来的研究中评估这种关联性以及它是否有助于预测。
{"title":"Comparison of complete blood count parameters in different severity of proteinuria among patients with type 2 diabetes mellitus.","authors":"Amirhesam Alirezaei, Kimia Karimi Toudeshki, Masoumeh Taherian, Hadi Pashapour, Fatemeh Rahmani, Najmeh Norouzi, Seyed Amirhossein Fazeli","doi":"10.4103/jrms.jrms_150_24","DOIUrl":"10.4103/jrms.jrms_150_24","url":null,"abstract":"<p><strong>Background: </strong>Proteinuria is a key indicator of kidney damage in diabetic nephropathy, and its severity correlates with the progression of the disease. In diabetic patients, it is crucial to identify reliable predictors for proteinuria and its severity for early detection and management of kidney damage.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted from November 16, 2022, to May 20, 2023, on patients with type 2 diabetes mellitus (T2DM) who were outpatients at clinics of Shahid Modarres Hospital, Tehran, Iran. Participants were categorized based on their level of proteinuria during 24-h as follows: group A1 (normal to mildly increased proteinuria), Group A2 (moderately increased proteinuria), and Group A3 (severely increased proteinuria). Then, complete blood cell count and other laboratory parameters, were compared between study groups.</p><p><strong>Results: </strong>In this cross-sectional study, 128 participants, including 53 (41.4%) men and 75 (58.6%) women with T2DM, were enrolled. The mean age of participants was 56.40 ± 13.31 years. Although there were no significant differences between cell count and parameters of three groups, a statistically significant difference was seen in neutrophil-to-lymphocyte ratio (NLR) (1.93 ± 0.76, 2.34 ± 0.93, and 2.73 ± 1.07 in A1, A2, and A3 groups, respectively; <i>P</i> = 0.003). Further analysis showed that NLR was significantly higher in Group A3 compared to A1 (2.73 ± 1.07 vs. 1.93 ± 0.76, respectively; <i>P</i> = 0.006), but there was no significant difference between Groups A3 and A2 (2.73 ± 1.07 vs. 2.34 ± 0.93, respectively; <i>P</i> = 0.482) and between Groups A2 and A1 (2.34 ± 0.93 vs. 1.93 ± 0.76, respectively; <i>P</i> = 0.257).</p><p><strong>Conclusion: </strong>Overall, this study suggests that some routine laboratory parameters may be associated with proteinuria and its severity in patients with T2DM. NLR, in particular, showed this association in our study, promising future studies evaluating this association and whether it can help as a predictor or not.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"66"},"PeriodicalIF":1.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11691054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional improvement for patients with stroke receiving postacute care rehabilitation program. 脑卒中患者急性期后护理康复方案的功能改善。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_62_23
Cheng-Che Wu, Ying-Hsun Chen, Hui-Chuan Huang, Kuan-Chia Lin

Background: Few studies explore the patient heterogeneity, trajectory development, and factors influencing the functional recovery of the postacute care cerebrovascular disease (PAC-CVD) program. The objective of the study was to analyze the group-based trajectory and different functional improvement for patients with acute stroke participating in the PAC-CVD program.

Materials and methods: A total of 328 patients with acute stroke who had participated in PAC-CVD program in rehabilitation departments of three hospitals from 2014 to 2017 were enrolled in this retrospective cohort study. Latent profile analysis (LPA) was applied to analyze the clinical characteristics between high- and low-function groups (LFGs). The analysis of variance and Chi-square test were used to analyze the association between functional grouping and patients' characteristics.

Results: In the study baseline, patients could be divided into high function group (HFG; 85/328 = 25.9%), medium function group (MFG; 128/328 = 39.02%), and (LFG; 115/328 = 35.06%) by LPA. age (P = 0.001), length of hospital stays (P = 0.001), male sex (P = 0.048), and lesion type (P = 0.023) were significantly associated with being grouped in the high-function group. After 6 weeks of rehabilitation training, 100% of HFG remained as HFG, 49.04% of MFG transitioned to HFG, and 50% of MFG continued to remain as MFG. 8.41% of LFG transitioned to HFG, 57% of LFG transitioned to MFG, but still, 34.58% of LFG continued to remain as LFG.

Conclusion: Identifying initial functional groups can guide medical professionals to target patients for PAC service use. PAC-CVD high-intensity rehabilitation significantly enhances acute stroke patients' functional recovery, though effectiveness varies over time. These factors highlight the need for further development of rehabilitation programs to boost patient independence.

背景:很少有研究探讨急性期脑血管病(PAC-CVD)术后患者的异质性、发展轨迹和影响功能恢复的因素。本研究的目的是分析急性脑卒中患者参与PAC-CVD计划的分组轨迹和不同功能改善情况。材料与方法:选取2014 - 2017年在三家医院康复科参加PAC-CVD项目的328例急性脑卒中患者进行回顾性队列研究。应用潜在剖面分析(Latent profile analysis, LPA)分析高功能组和低功能组的临床特征。采用方差分析和卡方检验分析功能分组与患者特征的相关性。结果:在研究基线中,患者可分为高功能组(HFG);85/328 = 25.9%),中等功能组(MFG;128/328 = 39.02%), (LFG;115/328 = 35.06%)。年龄(P = 0.001)、住院时间(P = 0.001)、男性(P = 0.048)和病变类型(P = 0.023)与归为高功能组有显著相关。经过6周的康复训练,100%的HFG保持为HFG, 49.04%的MFG过渡为HFG, 50%的MFG继续保持为MFG。8.41%的LFG转型为HFG, 57%的LFG转型为MFG,但仍有34.58%的LFG继续保持LFG。结论:明确初始功能群可以指导医务人员有针对性地使用PAC服务。PAC-CVD高强度康复可显著提高急性脑卒中患者的功能恢复,但效果随时间而变化。这些因素突出了进一步发展康复计划以提高患者独立性的必要性。
{"title":"Functional improvement for patients with stroke receiving postacute care rehabilitation program.","authors":"Cheng-Che Wu, Ying-Hsun Chen, Hui-Chuan Huang, Kuan-Chia Lin","doi":"10.4103/jrms.jrms_62_23","DOIUrl":"10.4103/jrms.jrms_62_23","url":null,"abstract":"<p><strong>Background: </strong>Few studies explore the patient heterogeneity, trajectory development, and factors influencing the functional recovery of the postacute care cerebrovascular disease (PAC-CVD) program. The objective of the study was to analyze the group-based trajectory and different functional improvement for patients with acute stroke participating in the PAC-CVD program.</p><p><strong>Materials and methods: </strong>A total of 328 patients with acute stroke who had participated in PAC-CVD program in rehabilitation departments of three hospitals from 2014 to 2017 were enrolled in this retrospective cohort study. Latent profile analysis (LPA) was applied to analyze the clinical characteristics between high- and low-function groups (LFGs). The analysis of variance and Chi-square test were used to analyze the association between functional grouping and patients' characteristics.</p><p><strong>Results: </strong>In the study baseline, patients could be divided into high function group (HFG; 85/328 = 25.9%), medium function group (MFG; 128/328 = 39.02%), and (LFG; 115/328 = 35.06%) by LPA. age (<i>P</i> = 0.001), length of hospital stays (<i>P</i> = 0.001), male sex (<i>P</i> = 0.048), and lesion type (<i>P</i> = 0.023) were significantly associated with being grouped in the high-function group. After 6 weeks of rehabilitation training, 100% of HFG remained as HFG, 49.04% of MFG transitioned to HFG, and 50% of MFG continued to remain as MFG. 8.41% of LFG transitioned to HFG, 57% of LFG transitioned to MFG, but still, 34.58% of LFG continued to remain as LFG.</p><p><strong>Conclusion: </strong>Identifying initial functional groups can guide medical professionals to target patients for PAC service use. PAC-CVD high-intensity rehabilitation significantly enhances acute stroke patients' functional recovery, though effectiveness varies over time. These factors highlight the need for further development of rehabilitation programs to boost patient independence.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"61"},"PeriodicalIF":1.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11691059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac rehabilitation is necessary for patients: Providing experiences from the launch of cardiac rehabilitation in a deprived province in Iran. 心脏康复对病人来说是必要的:提供在伊朗一个贫困省份开展心脏康复的经验。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_687_23
A Mirzaei Najmabadi, Maryam Sadat Rahimi, Seyed Mohammad Riahi, Toba Kazemi
{"title":"Cardiac rehabilitation is necessary for patients: Providing experiences from the launch of cardiac rehabilitation in a deprived province in Iran.","authors":"A Mirzaei Najmabadi, Maryam Sadat Rahimi, Seyed Mohammad Riahi, Toba Kazemi","doi":"10.4103/jrms.jrms_687_23","DOIUrl":"10.4103/jrms.jrms_687_23","url":null,"abstract":"","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"57"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of mesenchymal stem cell injections for knee osteoarthritis: A systematic review and meta-analysis. 间充质干细胞注射治疗膝关节骨关节炎的疗效和安全性:一项系统回顾和荟萃分析。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_515_23
Xinguang Zhang, Cunbao Cui, Feng Lin

Background: There have not been any clear studies on the use of mesenchymal stem cells (MSCs) to treat osteoarthritis (OA) in the knee.

Materials and methods: This study investigates the effects of different MSC dosages on pain alleviation in individuals with OA in the knee by conducting a meta-analysis of existing randomized controlled trials. Electronic resources such as Google Scholar, PubMed, Cochrane Library, and Web of Science were searched up until June 2023. Treatment effect sizes were computed using the knee osteoarthritis outcome score (KOOS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Knee Society Score (KSS). Random or fixed effect models were applied to aggregate the data. We performed a subgroup analysis according to dosage level. The heterogeneity of the research was investigated using the Chi-square test and the I2 index.

Results: The meta-analysis included 26 studies with a total sample size of 739 patients. A significant reduction in pain was observed 1 year and 2 years following the injection of MSCs into the injured joint, as indicated by the Visual Analogue Scale, WOMAC, KOOS, and KSS indexes (P < 0.05). Patients on MSCs reported much reduced pain after 1 and 2 years compared to the control group (P < 0.05). Subgroup and meta-regression analyses revealed no statistically significant variations in the effectiveness of MSC dosage (P < 0.05). The studies did not report any adverse effects.

Conclusion: Different dosages of MSCs had the same pain-relieving effects on patients with OA in the knee. MSC injections were safe and beneficial in such cases.

背景:使用间充质干细胞(MSCs)治疗膝关节骨关节炎(OA)尚无明确的研究。材料和方法:本研究通过对现有随机对照试验的荟萃分析,探讨了不同剂量的MSC对膝关节OA患者疼痛缓解的影响。截至2023年6月,b谷歌Scholar、PubMed、Cochrane Library和Web of Science等电子资源被检索。使用膝关节骨性关节炎结局评分(oos)、西安大略省和麦克马斯特大学骨关节炎指数(WOMAC)和膝关节社会评分(KSS)计算治疗效果大小。随机或固定效应模型应用于数据汇总。根据给药剂量进行亚组分析。采用卡方检验和I2指数对研究的异质性进行检验。结果:meta分析包括26项研究,总样本量为739例患者。视觉模拟评分、WOMAC、oos和KSS指数显示,MSCs注射损伤关节后1年和2年疼痛明显减轻(P < 0.05)。与对照组相比,接受MSCs治疗的患者在1年和2年后的疼痛明显减轻(P < 0.05)。亚组和荟萃回归分析显示,MSC剂量的有效性无统计学差异(P < 0.05)。这些研究没有报告任何副作用。结论:不同剂量间充质干细胞对膝关节OA患者的镇痛作用相同。在这种情况下,骨髓间充质干细胞注射是安全有益的。
{"title":"Efficacy and safety of mesenchymal stem cell injections for knee osteoarthritis: A systematic review and meta-analysis.","authors":"Xinguang Zhang, Cunbao Cui, Feng Lin","doi":"10.4103/jrms.jrms_515_23","DOIUrl":"10.4103/jrms.jrms_515_23","url":null,"abstract":"<p><strong>Background: </strong>There have not been any clear studies on the use of mesenchymal stem cells (MSCs) to treat osteoarthritis (OA) in the knee.</p><p><strong>Materials and methods: </strong>This study investigates the effects of different MSC dosages on pain alleviation in individuals with OA in the knee by conducting a meta-analysis of existing randomized controlled trials. Electronic resources such as Google Scholar, PubMed, Cochrane Library, and Web of Science were searched up until June 2023. Treatment effect sizes were computed using the knee osteoarthritis outcome score (KOOS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Knee Society Score (KSS). Random or fixed effect models were applied to aggregate the data. We performed a subgroup analysis according to dosage level. The heterogeneity of the research was investigated using the Chi-square test and the I2 index.</p><p><strong>Results: </strong>The meta-analysis included 26 studies with a total sample size of 739 patients. A significant reduction in pain was observed 1 year and 2 years following the injection of MSCs into the injured joint, as indicated by the Visual Analogue Scale, WOMAC, KOOS, and KSS indexes (P < 0.05). Patients on MSCs reported much reduced pain after 1 and 2 years compared to the control group (P < 0.05). Subgroup and meta-regression analyses revealed no statistically significant variations in the effectiveness of MSC dosage (P < 0.05). The studies did not report any adverse effects.</p><p><strong>Conclusion: </strong>Different dosages of MSCs had the same pain-relieving effects on patients with OA in the knee. MSC injections were safe and beneficial in such cases.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"55"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effects of humor therapy on fatigue levels of hemodialysis patients: A single-blind, randomized clinical trial study. 评价幽默疗法对血液透析患者疲劳水平的影响:一项单盲、随机临床试验研究。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_17_23
Mohammad Sahebkar, Mojgan Ansari, Farnush Attarzadeh, Fateme Borzoee

Background: This study investigated the effects of humor therapy on the fatigue levels of patients receiving hemodialysis (HD).

Materials and methods: A single-blind, randomized clinical trial of 66 HD patients for 3 weeks was conducted, in which two groups were randomly allocated - humor therapy and control. In the intervention group, humor therapy sessions were conducted twice a week for 3 weeks. As a pre- and postintervention assessment, the Fatigue Symptom Inventory (FSI) was completed.

Results: According to the repeated-measures ANOVA test, FSI values exhibited a significant decline in the humor therapy group and an increase in the control group at the first, second, and third visits (humor therapy vs. control: 30.38 ± 8.75 and 61.80 ± 13.92, P < 0.001; 35.71 ± 10.05 and 69.53 ± 15.32, P < 0.001; and 34.85 ± 9.24 and 70.34 ± 22.26, P < 0.001, respectively) compared with baseline (humor therapy vs. control: 49.26 ± 5.19 and 52.09 ± 11.69, P = 0.204).

Conclusion: Findings suggest that humor therapy can effectively reduce fatigue levels in patients presenting with HD.

背景:本研究探讨了幽默疗法对血液透析(HD)患者疲劳水平的影响。材料与方法:对66例HD患者进行为期3周的单盲随机临床试验,随机分为幽默治疗组和对照组。干预组每周进行两次幽默治疗,持续3周。作为干预前和干预后的评估,疲劳症状量表(FSI)完成。结果:根据重复测量方差分析,在第一次、第二次和第三次就诊时,幽默治疗组的FSI值显著下降,对照组的FSI值显著升高(幽默治疗组与对照组相比:30.38±8.75和61.80±13.92,P < 0.001;35.71±10.05和69.53±15.32,P < 0.001;分别为34.85±9.24和70.34±22.26,P < 0.001)(幽默治疗组与对照组分别为49.26±5.19和52.09±11.69,P = 0.204)。结论:幽默疗法能有效降低HD患者的疲劳水平。
{"title":"Evaluating the effects of humor therapy on fatigue levels of hemodialysis patients: A single-blind, randomized clinical trial study.","authors":"Mohammad Sahebkar, Mojgan Ansari, Farnush Attarzadeh, Fateme Borzoee","doi":"10.4103/jrms.jrms_17_23","DOIUrl":"10.4103/jrms.jrms_17_23","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the effects of humor therapy on the fatigue levels of patients receiving hemodialysis (HD).</p><p><strong>Materials and methods: </strong>A single-blind, randomized clinical trial of 66 HD patients for 3 weeks was conducted, in which two groups were randomly allocated - humor therapy and control. In the intervention group, humor therapy sessions were conducted twice a week for 3 weeks. As a pre- and postintervention assessment, the Fatigue Symptom Inventory (FSI) was completed.</p><p><strong>Results: </strong>According to the repeated-measures ANOVA test, FSI values exhibited a significant decline in the humor therapy group and an increase in the control group at the first, second, and third visits (humor therapy vs. control: 30.38 ± 8.75 and 61.80 ± 13.92, <i>P</i> < 0.001; 35.71 ± 10.05 and 69.53 ± 15.32, <i>P</i> < 0.001; and 34.85 ± 9.24 and 70.34 ± 22.26, <i>P</i> < 0.001, respectively) compared with baseline (humor therapy vs. control: 49.26 ± 5.19 and 52.09 ± 11.69, <i>P</i> = 0.204).</p><p><strong>Conclusion: </strong>Findings suggest that humor therapy can effectively reduce fatigue levels in patients presenting with HD.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"56"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019. 原发性胆道胆管炎进展和预后相关因素:2010-2019年队列研究
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_813_22
Sayed Mohammad Javad Sajadi, Babak Tamizifar, Mohammad Hossein Sanei, Anahita Babak

Background: Primary biliary cholangitis (PBC) can impact both the quality of life and the survival of patients. The study aimed to determine the survival rate and associated variables in patients with PBC.

Materials and methods: This cohort research comprised 65 patients diagnosed with PBC who were admitted to the pathology section between January 2010 and December 2019. Survival was determined by reviewing hospital medical data and following up with the patients. The impact of demographic factors, clinical, laboratory, and histopathological aspects on patient survival time was investigated using Kaplan-Meier survival analysis and Cox regression.

Results: The average period of follow-up was 6.25 years with a standard deviation of 3.2 years. In surviving patients, the baseline bilirubin level was 2.83, but in deceased or transplanted patients, it was 8.95 (P = 0.002). The baseline albumin level was 3.99 in surviving patients and 3.66 in deceased or transplanted patients (P = 0.024). The incidence of cirrhosis in those who survived was 1.8%, but in patients who died or underwent a transplant, it was 40%. Out of 65 cases, 3 patients (4.7%) died and 7 (10%) had liver transplants. Survival rates of patients vary based on factors such as jaundice (P = 0.002), weariness (P = 0.03), cirrhosis (P < 0.001), and vitiligo (P = 0.033). There were notable variations in the average Mayo score between the two groups of patients who had liver transplantation and survived, with scores of 7.21 and 5.61, respectively.

Conclusion: The study found that aspartate aminotransferase and alanine aminotransferase levels, baseline and final bilirubin, albumin, antinuclear antibody, the presence of cirrhosis, and jaundice significantly influenced patient survival with PBC.

背景:原发性胆道胆管炎(PBC)可以影响患者的生活质量和生存。该研究旨在确定PBC患者的生存率和相关变量。材料和方法:本队列研究纳入了2010年1月至2019年12月病理科收治的65例确诊为PBC的患者。生存率是通过回顾医院医疗数据和随访患者来确定的。采用Kaplan-Meier生存分析和Cox回归研究人口统计学因素、临床、实验室和组织病理学方面对患者生存时间的影响。结果:平均随访时间为6.25年,标准差为3.2年。存活患者的基线胆红素水平为2.83,而死亡或移植患者的基线胆红素水平为8.95 (P = 0.002)。存活患者的基线白蛋白水平为3.99,死亡或移植患者的基线白蛋白水平为3.66 (P = 0.024)。存活患者的肝硬化发病率为1.8%,但死亡或接受移植的患者的肝硬化发病率为40%。65例患者中,死亡3例(4.7%),行肝移植7例(10%)。患者的生存率因黄疸(P = 0.002)、疲劳(P = 0.03)、肝硬化(P < 0.001)和白癜风(P = 0.033)等因素而异。两组肝移植存活患者的平均Mayo评分差异显著,分别为7.21分和5.61分。结论:研究发现,天冬氨酸转氨酶和丙氨酸转氨酶水平、基线和最终胆红素、白蛋白、抗核抗体、肝硬化和黄疸的存在显著影响PBC患者的生存。
{"title":"Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019.","authors":"Sayed Mohammad Javad Sajadi, Babak Tamizifar, Mohammad Hossein Sanei, Anahita Babak","doi":"10.4103/jrms.jrms_813_22","DOIUrl":"10.4103/jrms.jrms_813_22","url":null,"abstract":"<p><strong>Background: </strong>Primary biliary cholangitis (PBC) can impact both the quality of life and the survival of patients. The study aimed to determine the survival rate and associated variables in patients with PBC.</p><p><strong>Materials and methods: </strong>This cohort research comprised 65 patients diagnosed with PBC who were admitted to the pathology section between January 2010 and December 2019. Survival was determined by reviewing hospital medical data and following up with the patients. The impact of demographic factors, clinical, laboratory, and histopathological aspects on patient survival time was investigated using Kaplan-Meier survival analysis and Cox regression.</p><p><strong>Results: </strong>The average period of follow-up was 6.25 years with a standard deviation of 3.2 years. In surviving patients, the baseline bilirubin level was 2.83, but in deceased or transplanted patients, it was 8.95 (<i>P</i> = 0.002). The baseline albumin level was 3.99 in surviving patients and 3.66 in deceased or transplanted patients (<i>P</i> = 0.024). The incidence of cirrhosis in those who survived was 1.8%, but in patients who died or underwent a transplant, it was 40%. Out of 65 cases, 3 patients (4.7%) died and 7 (10%) had liver transplants. Survival rates of patients vary based on factors such as jaundice (<i>P</i> = 0.002), weariness (<i>P</i> = 0.03), cirrhosis (<i>P</i> < 0.001), and vitiligo (<i>P</i> = 0.033). There were notable variations in the average Mayo score between the two groups of patients who had liver transplantation and survived, with scores of 7.21 and 5.61, respectively.</p><p><strong>Conclusion: </strong>The study found that aspartate aminotransferase and alanine aminotransferase levels, baseline and final bilirubin, albumin, antinuclear antibody, the presence of cirrhosis, and jaundice significantly influenced patient survival with PBC.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"59"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of low-frequency blood glucose self-monitoring on glycosylated hemoglobin levels among older adults with type 2 diabetes mellitus. 低频血糖自我监测对老年2型糖尿病患者糖化血红蛋白水平的影响。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_20_23
Mohammad Sahebkar, Atousa Ariafar, Farnush Attarzadeh, Najmeh Rahimi, Susan J Malkemes, Mohammad Hassan Rakhshani, Abdolghader Assarroudi

Background: Reducing the frequency of self-monitoring of blood sugar, due to needle phobia, pain, stress, and costs associated with the procedure, can improve patient compliance and quality of life, provided that adequate blood sugar control is maintained. This study aimed to evaluate the effect of low-frequency blood glucose self-monitoring (LFBGSM) on glycosylated hemoglobin (HbA1C) levels among older adults living with type 2 diabetes mellitus (T2DM), treated with or without insulin.

Materials and methods: This randomized controlled trial with a parallel design was conducted on 121 older adults with T2DM in Sabzevar, Iran, between 2018 and 2020. Initially, subjects were stratified based on the type of treatment (with or without insulin) and then randomly assigned to intervention (LFBGSM) and control (no blood glucose self-monitoring [no-BGSM]) groups. HbA1C levels were measured at the beginning of the study and 3 months later for all study groups.

Results: The mean age of participants treated with and without insulin was 64.3 ± 9.60 and 64.7 ± 5.01 years, respectively. The ANCOVA test revealed a significant difference in the mean HbA1C levels among the four groups 3 months postintervention (P < 0.001). The HbA1C scores significantly decreased in the LFBGSM groups and increased in the no-BGSM groups at 3 months postintervention (insulin/LFBGSM, insulin/no-BGSM, noninsulin/LFBGSM, and noninsulin/no-BGSM: 7.74 ± 0.76, 8.34 ± 1.53, 7.70 ± 0.75, and 8.14 ± 1.11, respectively) compared to baseline (8.25 ± 0.67, 8.03 ± 0.64, 8.08 ± 0.69, and 7.83 ± 0.74, respectively). The least significant difference post hoc tests showed significant differences between specific groups, emphasizing subtle responses to interventions (P values ranging from 0.001 to 0.929).

Conclusion: Findings suggest a significant reduction in HbA1C scores within the LFBGSM groups, while a discernible increase is observed in the no-BGSM groups over the 3 months. These findings underscore the efficacy of the interventions and emphasize the crucial role of personalized approaches in optimizing glycemic control for individuals with diabetes.

背景:减少自我监测血糖的频率,由于针头恐惧,疼痛,压力和与手术相关的费用,可以提高患者的依从性和生活质量,前提是保持适当的血糖控制。本研究旨在评估低频血糖自我监测(LFBGSM)对老年2型糖尿病(T2DM)患者(接受或不接受胰岛素治疗)糖化血红蛋白(HbA1C)水平的影响。材料和方法:该随机对照试验采用平行设计,于2018年至2020年在伊朗Sabzevar对121名老年T2DM患者进行了研究。最初,受试者根据治疗类型(使用或不使用胰岛素)进行分层,然后随机分配到干预组(LFBGSM)和对照组(无血糖自我监测[无bgsm])。在研究开始时和3个月后对所有研究组的HbA1C水平进行测量。结果:胰岛素治疗组和非胰岛素治疗组的平均年龄分别为64.3±9.60岁和64.7±5.01岁。ANCOVA检验显示,干预后3个月,四组患者的平均HbA1C水平有显著差异(P < 0.001)。干预后3个月,与基线(8.25±0.67,8.03±0.64,8.08±0.69,7.83±0.74)相比,LFBGSM组(胰岛素/LFBGSM,胰岛素/无bgsm,非胰岛素/LFBGSM,非胰岛素/无bgsm)的HbA1C评分显著降低,无bgsm组(分别为7.74±0.76,8.34±1.53,7.70±0.75,8.14±1.11)的HbA1C评分显著升高。最不显著差异事后检验显示特定组之间存在显著差异,强调对干预措施的微妙反应(P值范围为0.001至0.929)。结论:研究结果表明,在3个月内,LFBGSM组的HbA1C评分显著降低,而非bgsm组的HbA1C评分明显升高。这些发现强调了干预措施的有效性,并强调了个性化方法在优化糖尿病患者血糖控制中的关键作用。
{"title":"Effect of low-frequency blood glucose self-monitoring on glycosylated hemoglobin levels among older adults with type 2 diabetes mellitus.","authors":"Mohammad Sahebkar, Atousa Ariafar, Farnush Attarzadeh, Najmeh Rahimi, Susan J Malkemes, Mohammad Hassan Rakhshani, Abdolghader Assarroudi","doi":"10.4103/jrms.jrms_20_23","DOIUrl":"10.4103/jrms.jrms_20_23","url":null,"abstract":"<p><strong>Background: </strong>Reducing the frequency of self-monitoring of blood sugar, due to needle phobia, pain, stress, and costs associated with the procedure, can improve patient compliance and quality of life, provided that adequate blood sugar control is maintained. This study aimed to evaluate the effect of low-frequency blood glucose self-monitoring (LFBGSM) on glycosylated hemoglobin (HbA1<sub>C</sub>) levels among older adults living with type 2 diabetes mellitus (T2DM), treated with or without insulin.</p><p><strong>Materials and methods: </strong>This randomized controlled trial with a parallel design was conducted on 121 older adults with T2DM in Sabzevar, Iran, between 2018 and 2020. Initially, subjects were stratified based on the type of treatment (with or without insulin) and then randomly assigned to intervention (LFBGSM) and control (no blood glucose self-monitoring [no-BGSM]) groups. HbA1<sub>C</sub> levels were measured at the beginning of the study and 3 months later for all study groups.</p><p><strong>Results: </strong>The mean age of participants treated with and without insulin was 64.3 ± 9.60 and 64.7 ± 5.01 years, respectively. The ANCOVA test revealed a significant difference in the mean HbA1<sub>C</sub> levels among the four groups 3 months postintervention (<i>P</i> < 0.001). The HbA1<sub>C</sub> scores significantly decreased in the LFBGSM groups and increased in the no-BGSM groups at 3 months postintervention (insulin/LFBGSM, insulin/no-BGSM, noninsulin/LFBGSM, and noninsulin/no-BGSM: 7.74 ± 0.76, 8.34 ± 1.53, 7.70 ± 0.75, and 8.14 ± 1.11, respectively) compared to baseline (8.25 ± 0.67, 8.03 ± 0.64, 8.08 ± 0.69, and 7.83 ± 0.74, respectively). The least significant difference <i>post</i> <i>hoc</i> tests showed significant differences between specific groups, emphasizing subtle responses to interventions (<i>P</i> values ranging from 0.001 to 0.929).</p><p><strong>Conclusion: </strong>Findings suggest a significant reduction in HbA1<sub>C</sub> scores within the LFBGSM groups, while a discernible increase is observed in the no-BGSM groups over the 3 months. These findings underscore the efficacy of the interventions and emphasize the crucial role of personalized approaches in optimizing glycemic control for individuals with diabetes.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"58"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis. 西马鲁肽治疗伴有或不伴有2型糖尿病的超重/肥胖成人的有效性和安全性:一项系统综述和荟萃分析
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_693_23
Liu Yang, Xueyu Duan, Peng Hua, Shilin Wu, Xiaobo Liu

Background: The objective of the study was to systematically evaluate the efficacy and safety of semaglutide in overweight or obese adults with or without type 2 diabetes.

Materials and methods: The study, registered with PROSPERO (CRD42023450979), was designed as a systematic review and meta-analysis. Using a combination of subject matter and free words, a comprehensive search of Embase, PubMed, and Cochrane Library databases was performed to identify randomized controlled trials of semaglutide in overweight or obese adults with or without Type 2 diabetes mellitus from January 1, 2020, to July 14, 2023. The primary outcomes were the changes in body weight and adverse drug reaction (ADR). Random or fixed effects models were used in meta-analysis, pooling data as relative risks (RRs) or mean difference (MD) with 95% confidence intervals (CIs). Cochrane Collaboration's Risk of Bias tool was used to assess quality. Meta-analysis was performed using RevMan 5.3.

Results: A total of 2490 publications were retrieved. Fifteen publications were finally included, totaling 6984 overweight or obese adult patients. Meta-analysis showed that compared with the control group, the semaglutide group was reduced more significantly in body weight (MD = -7.49, 95% CI [-9.92, -5.07], P < 0.001), body mass index (MD = -3.35, 95% CI [-4.79, -1.92], P < 0.001), waist circumference (MD = -7.26, 95% CI [-9.94, -4.58], P < 0.001), as well as glycosylated hemoglobin (RR = -0.66, 95% CI [-1.07, -0.25], P = 0.002), fasting blood glucose values (RR = -4.81, 95% CI [-7.03, -2.60], P < 0.001), and systolic blood pressure (RR = -3.37, 95% CI [-5.32, -1.42], P < 0.001), and the proportion of patients who lost > 5%, 10%, 15%, and 20% of their overall body weight, respectively (RR = 3.19, 95% CI [1.89, 5.36], P < 0.001), (RR = 4.74, 95% CI [2.78, 8.11], P < 0.001), (RR = 6.17, 95% CI [3.88, 9.82], P < 0.001), and (RR = 9.14, 95% CI [6.05, 13.80], P < 0.001) were also superior to the control group. Regarding safety, the incidence of total ADR in the semaglutide group was close to the placebo group. Still, gastrointestinal adverse effects such as nausea, vomiting, abdominal pain, and diarrhea were higher than those in the control group.

Conclusion: Semaglutide can effectively lose weight in overweight or obese adults with or without diabetes, potentially providing cardiovascular benefits; however, gastrointestinal adverse should be closely monitored.

背景:本研究的目的是系统评价西马鲁肽治疗超重或肥胖成人伴或不伴2型糖尿病的疗效和安全性。材料和方法:该研究已在PROSPERO注册(CRD42023450979),设计为系统评价和荟萃分析。结合主题和自由词,对Embase、PubMed和Cochrane图书馆数据库进行了全面检索,以确定2020年1月1日至2023年7月14日期间,西马鲁肽用于超重或肥胖的伴有或不伴有2型糖尿病的成年人的随机对照试验。主要观察指标为体重变化和药物不良反应(ADR)。meta分析中使用随机或固定效应模型,将数据汇总为相对风险(rr)或95%置信区间(ci)的平均差异(MD)。采用Cochrane Collaboration的风险偏倚工具评估质量。采用RevMan 5.3进行meta分析。结果:共检索文献2490篇。最终纳入15篇出版物,共6984例超重或肥胖成年患者。荟萃分析显示,与对照组相比,semaglutide组降低更明显的体重(MD = -7.49, 95% CI [-9.92, -5.07], P < 0.001),身体质量指数(MD = -3.35, 95% CI [-4.79, -1.92], P < 0.001),腰围(MD = -7.26, 95% CI [-9.94, -4.58], P < 0.001),以及糖化血红蛋白(RR = -0.66, 95%可信区间[-1.07,-0.25],P = 0.002),空腹血糖值(RR = -4.81, 95%可信区间[-7.03,-2.60],P < 0.001),和收缩压(RR = -3.37, 95% CI [-5.32, -1.42], P < 0.001),患者的比例> 5%,10%,15%,和20%的整体体重分别(RR = 3.19, 95%可信区间[1.89,5.36],P < 0.001), (RR = 4.74, 95%可信区间[2.78,8.11],P < 0.001), (RR = 6.17, 95%可信区间[3.88,9.82],P < 0.001),和(RR = 9.14, 95%可信区间[6.05,13.80],P < 0.001)也优于对照组。在安全性方面,西马鲁肽组的总不良反应发生率接近安慰剂组。尽管如此,胃肠道不良反应,如恶心、呕吐、腹痛和腹泻,仍高于对照组。结论:Semaglutide可以有效地减轻超重或肥胖成人伴或不伴糖尿病的体重,潜在地提供心血管益处;但应密切监测胃肠道不良反应。
{"title":"Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.","authors":"Liu Yang, Xueyu Duan, Peng Hua, Shilin Wu, Xiaobo Liu","doi":"10.4103/jrms.jrms_693_23","DOIUrl":"10.4103/jrms.jrms_693_23","url":null,"abstract":"<p><strong>Background: </strong>The objective of the study was to systematically evaluate the efficacy and safety of semaglutide in overweight or obese adults with or without type 2 diabetes.</p><p><strong>Materials and methods: </strong>The study, registered with PROSPERO (CRD42023450979), was designed as a systematic review and meta-analysis. Using a combination of subject matter and free words, a comprehensive search of Embase, PubMed, and Cochrane Library databases was performed to identify randomized controlled trials of semaglutide in overweight or obese adults with or without Type 2 diabetes mellitus from January 1, 2020, to July 14, 2023. The primary outcomes were the changes in body weight and adverse drug reaction (ADR). Random or fixed effects models were used in meta-analysis, pooling data as relative risks (RRs) or mean difference (MD) with 95% confidence intervals (CIs). Cochrane Collaboration's Risk of Bias tool was used to assess quality. Meta-analysis was performed using RevMan 5.3.</p><p><strong>Results: </strong>A total of 2490 publications were retrieved. Fifteen publications were finally included, totaling 6984 overweight or obese adult patients. Meta-analysis showed that compared with the control group, the semaglutide group was reduced more significantly in body weight (MD = -7.49, 95% CI [-9.92, -5.07], <i>P</i> < 0.001), body mass index (MD = -3.35, 95% CI [-4.79, -1.92], <i>P</i> < 0.001), waist circumference (MD = -7.26, 95% CI [-9.94, -4.58], <i>P</i> < 0.001), as well as glycosylated hemoglobin (RR = -0.66, 95% CI [-1.07, -0.25], <i>P</i> = 0.002), fasting blood glucose values (RR = -4.81, 95% CI [-7.03, -2.60], <i>P</i> < 0.001), and systolic blood pressure (RR = -3.37, 95% CI [-5.32, -1.42], <i>P</i> < 0.001), and the proportion of patients who lost > 5%, 10%, 15%, and 20% of their overall body weight, respectively (RR = 3.19, 95% CI [1.89, 5.36], <i>P</i> < 0.001), (RR = 4.74, 95% CI [2.78, 8.11], <i>P</i> < 0.001), (RR = 6.17, 95% CI [3.88, 9.82], <i>P</i> < 0.001), and (RR = 9.14, 95% CI [6.05, 13.80], <i>P</i> < 0.001) were also superior to the control group. Regarding safety, the incidence of total ADR in the semaglutide group was close to the placebo group. Still, gastrointestinal adverse effects such as nausea, vomiting, abdominal pain, and diarrhea were higher than those in the control group.</p><p><strong>Conclusion: </strong>Semaglutide can effectively lose weight in overweight or obese adults with or without diabetes, potentially providing cardiovascular benefits; however, gastrointestinal adverse should be closely monitored.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"60"},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive function and brain magnetic resonance imaging profiles in neuromyelitis optica spectrum disorder and multiple sclerosis. 神经脊髓炎视谱系障碍和多发性硬化症的认知功能和脑磁共振成像特征。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-02 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_703_23
Fereshteh Ashtari, Pouran Najarzadeh, Vahid Shaygannejad, Iman Adibi, Neda Ramezani, Fariba Davanian, Sahar Akbaripour, Majid Barekatain

Background: The objective of this study was to investigate cognitive performance and brain volume profile in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS).

Materials and methods: In a historical cohort study, 29 MS patients, 31 NMOSD patients, and 20 healthy controls (HCs) underwent neuropsychological assessment using the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). Patients with MS and NMOSD also underwent a 1.5-tesla magnetic resonance imaging scan and high-resolution three-dimensional T1-weighted MPRAGE sequence.

Results: The Symbol Digit Modalities Test scores were significantly lower in MS (mean [standard deviation (SD)] =44.1 [14]) and NMOSD (mean [SD] =45.5 [14.3]) patients compared to HCs (mean [SD] =57 [9.5], P < 0.001). Scores of the Controlled Oral Word Association Test were also lower in MS (mean [SD] =25.9 [9.8]) and NMOSD (mean [SD] =24.6 [10.2]) patients compared to HCs (mean [SD] =36.6 [9.8], P < 0.001). Additionally, the MS group performed worse on the Brief Visuospatial Memory Test (BVMT) compared to the NMOSD group (9.4 ± 3.4 vs. 7.1 ± 3.7 P < 0.001). In MS patients, there was a significant correlation between all cognition scores and total brain lesions, as well as between every test except BVMT-Revised with thalamic volumes. In NMOSD patients, a correlation was found between gray matter volume and the learning phase of the California Verbal Learning Test-II as well as between total lesion percentage and verbal memory and information processing speed.

Conclusion: Both NMOSD and MS patients experienced impairment of information processing speed, working memory, and verbal fluency, whereas visuospatial memory impairment was only observed in MS patients. Despite lower total brain lesion and less thalamic atrophy, patients with NMOSD are at risk of cognitive impairment. Microscopic structural abnormalities may be a possible cause.

研究背景本研究的目的是调查神经脊髓炎视网膜频谱障碍(NMOSD)和多发性硬化症(MS)患者的认知能力和脑容量概况:在一项历史性队列研究中,29 名多发性硬化症患者、31 名 NMOSD 患者和 20 名健康对照组(HCs)使用多发性硬化症认知功能最低评估(MACFIMS)进行了神经心理学评估。多发性硬化症和 NMOSD 患者还接受了 1.5 特斯拉磁共振成像扫描和高分辨率三维 T1 加权 MPRAGE 序列:与普通人(平均[标准差(SD)] =57 [9.5],P < 0.001)相比,多发性硬化症患者(平均[标准差(SD)] =44.1 [14])和非多发性硬化症患者(平均[标准差(SD)] =45.5 [14.3])的符号数字模态测试得分明显较低。与普通人相比,多发性硬化症(平均[标码] =25.9 [9.8])和非多发性硬化症(平均[标码] =24.6 [10.2])患者的控制性口语单词联想测验分数也较低(平均[标码] =36.6 [9.8],P < 0.001)。此外,与 NMOSD 组相比,多发性硬化症组在简短视觉空间记忆测试 (BVMT) 中的表现更差(9.4 ± 3.4 vs. 7.1 ± 3.7,P < 0.001)。在多发性硬化症患者中,所有认知评分与脑部总病变之间以及除BVMT-Revised之外的所有测试与丘脑体积之间均存在显著相关性。在NMOSD患者中,灰质体积与加州言语学习测试-II的学习阶段之间存在相关性,总病变百分比与言语记忆和信息处理速度之间也存在相关性:结论:NMOSD 和多发性硬化症患者的信息处理速度、工作记忆和言语流畅性均受到损害,而只有多发性硬化症患者的视觉空间记忆受到损害。尽管NMOSD患者的脑部总病变较少,丘脑萎缩程度也较轻,但他们仍有认知功能受损的风险。微观结构异常可能是一个原因。
{"title":"Cognitive function and brain magnetic resonance imaging profiles in neuromyelitis optica spectrum disorder and multiple sclerosis.","authors":"Fereshteh Ashtari, Pouran Najarzadeh, Vahid Shaygannejad, Iman Adibi, Neda Ramezani, Fariba Davanian, Sahar Akbaripour, Majid Barekatain","doi":"10.4103/jrms.jrms_703_23","DOIUrl":"https://doi.org/10.4103/jrms.jrms_703_23","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to investigate cognitive performance and brain volume profile in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS).</p><p><strong>Materials and methods: </strong>In a historical cohort study, 29 MS patients, 31 NMOSD patients, and 20 healthy controls (HCs) underwent neuropsychological assessment using the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). Patients with MS and NMOSD also underwent a 1.5-tesla magnetic resonance imaging scan and high-resolution three-dimensional T1-weighted MPRAGE sequence.</p><p><strong>Results: </strong>The Symbol Digit Modalities Test scores were significantly lower in MS (mean [standard deviation (SD)] =44.1 [14]) and NMOSD (mean [SD] =45.5 [14.3]) patients compared to HCs (mean [SD] =57 [9.5], <i>P</i> < 0.001). Scores of the Controlled Oral Word Association Test were also lower in MS (mean [SD] =25.9 [9.8]) and NMOSD (mean [SD] =24.6 [10.2]) patients compared to HCs (mean [SD] =36.6 [9.8], <i>P</i> < 0.001). Additionally, the MS group performed worse on the Brief Visuospatial Memory Test (BVMT) compared to the NMOSD group (9.4 ± 3.4 vs. 7.1 ± 3.7 <i>P</i> < 0.001). In MS patients, there was a significant correlation between all cognition scores and total brain lesions, as well as between every test except BVMT-Revised with thalamic volumes. In NMOSD patients, a correlation was found between gray matter volume and the learning phase of the California Verbal Learning Test-II as well as between total lesion percentage and verbal memory and information processing speed.</p><p><strong>Conclusion: </strong>Both NMOSD and MS patients experienced impairment of information processing speed, working memory, and verbal fluency, whereas visuospatial memory impairment was only observed in MS patients. Despite lower total brain lesion and less thalamic atrophy, patients with NMOSD are at risk of cognitive impairment. Microscopic structural abnormalities may be a possible cause.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"49"},"PeriodicalIF":1.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of malaria in saravan city and its suburbs from 2018 to 2023, Southeast Iran. 2018年至2023年伊朗东南部萨拉万市及其郊区的疟疾流行病学。
IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-02 eCollection Date: 2024-01-01 DOI: 10.4103/jrms.jrms_781_23
Shaghayegh Dabirzadeh, Hamidaldin Bayegan, Mahdi Rezaei Kahkhazhaleh, Mansour Dabirzadeh

Background: Malaria, transmitted by Plasmodium parasites and anopheline mosquitoes, continues to be a leading cause of global disease and death. This retrospective investigation from 2018 to 2023 examines the epidemiological attributes of malaria in Saravan, southeastern Iran. It seeks to evaluate the prevalence, transmission causes, local population impact, and health system effects.

Materials and methods: Blood samples from suspected malaria cases in Saravan health centers were collected for this analysis. Each positive case was detailed with demographic data in a questionnaire. The SPSS 26 statistical program scrutinized data with t-tests comparing the variables.

Results: The study indicated fluctuating malaria cases peaking in 2023, with an annual parasite incidence. (API) of 17.27. Plasmodium vivax was the predominant species (P < 0.001), with the majority of cases in individuals over 15, notably males. A significant number of cases were reported in September (20.7%).

Conclusion: The findings emphasize the persistent malaria challenges in Saravan, accentuating the urgent need to strengthen prevention and control strategies. Reducing disease burden demands focused approaches, including improving prevention and treatment programs, enhancing surveillance systems, developing health infrastructures, and implementing localized therapies, especially considering recent climatic and rainfall patterns.

背景:疟疾由疟原虫和疟蚊传播,仍然是全球疾病和死亡的主要原因。这项从 2018 年到 2023 年的回顾性调查研究了伊朗东南部萨拉万的疟疾流行病学特征。调查旨在评估疟疾的流行率、传播原因、对当地人口的影响以及对卫生系统的影响:本次分析收集了萨拉万医疗中心疑似疟疾病例的血液样本。每个阳性病例都在问卷中详细列出了人口统计学数据。SPSS 26 统计程序对数据进行了仔细分析,并对变量进行了 t 检验:研究表明,疟疾病例呈波动趋势,在 2023 年达到高峰,年寄生虫发病率为 17.27。(API) 为 17.27。主要寄生虫为间日疟原虫(P < 0.001),大多数病例发生在 15 岁以上的人群中,尤其是男性。大量病例发生在 9 月份(20.7%):研究结果表明,萨拉万地区面临着长期的疟疾挑战,迫切需要加强预防和控制策略。减轻疾病负担需要有针对性的方法,包括改进预防和治疗计划、加强监测系统、发展卫生基础设施和实施本地化疗法,特别是考虑到最近的气候和降雨模式。
{"title":"Epidemiology of malaria in saravan city and its suburbs from 2018 to 2023, Southeast Iran.","authors":"Shaghayegh Dabirzadeh, Hamidaldin Bayegan, Mahdi Rezaei Kahkhazhaleh, Mansour Dabirzadeh","doi":"10.4103/jrms.jrms_781_23","DOIUrl":"https://doi.org/10.4103/jrms.jrms_781_23","url":null,"abstract":"<p><strong>Background: </strong>Malaria, transmitted by <i>Plasmodium</i> parasites and anopheline mosquitoes, continues to be a leading cause of global disease and death. This retrospective investigation from 2018 to 2023 examines the epidemiological attributes of malaria in Saravan, southeastern Iran. It seeks to evaluate the prevalence, transmission causes, local population impact, and health system effects.</p><p><strong>Materials and methods: </strong>Blood samples from suspected malaria cases in Saravan health centers were collected for this analysis. Each positive case was detailed with demographic data in a questionnaire. The SPSS 26 statistical program scrutinized data with <i>t</i>-tests comparing the variables.</p><p><strong>Results: </strong>The study indicated fluctuating malaria cases peaking in 2023, with an annual parasite incidence. (API) of 17.27. <i>Plasmodium vivax</i> was the predominant species (<i>P</i> < 0.001), with the majority of cases in individuals over 15, notably males. A significant number of cases were reported in September (20.7%).</p><p><strong>Conclusion: </strong>The findings emphasize the persistent malaria challenges in Saravan, accentuating the urgent need to strengthen prevention and control strategies. Reducing disease burden demands focused approaches, including improving prevention and treatment programs, enhancing surveillance systems, developing health infrastructures, and implementing localized therapies, especially considering recent climatic and rainfall patterns.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"50"},"PeriodicalIF":1.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Medical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1